Cancer drug prices to fall by up to 96% from 9 November: how the NPPA margin cap works
The National Pharmaceutical Pricing Authority has capped trade margins on 137 non-scheduled anti-cancer medicines at 30% of the maximum retail price. Revised prices take effect on 9 November 2026, with the largest reported reduction at 96.45%.
From 9 November 2026, the prices of more than 1,000 anti-cancer medicine formulations are set to fall after the National Pharmaceutical Pricing Authority (NPPA) capped trade margins on 137 non-scheduled anti-cancer medicines at 30% of the maximum retail price (MRP), excluding GST. The order was issued on 17 October 2026 under the Drugs (Prices Control) Order, 2013. Reported price reductions average between 20% and 70%, with the largest single reported reduction at 96.45%, and the government has put estimated patient savings at about Rs 3,357 crore to Rs 3,502 crore a year, depending on the figure used. Not every cancer medicine is covered, and the cap controls the price of medicines, not the full cost of cancer treatment.
What changes on 9 November 2026
From Monday, 9 November 2026, revised prices take effect for anti-cancer medicines covered by the National Pharmaceutical Pricing Authority's trade-margin order. The NPPA, which works under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilizers, issued the order on 17 October 2026, capping trade margins at 30 per cent of the maximum retail price (MRP) of the identified medicines, excluding Goods and Services Tax (GST).
The order covers 137 non-scheduled anti-cancer medicines, and the price cuts apply across their strengths, dosage forms and combinations, including branded and generic products, imported medicines and medicines protected by patents. According to the NPPA, 76 pharmaceutical companies had by then reported revised MRPs for 1,225 formulations covering 121 drugs, and price reductions had been reported in 1,031 formulations, with 600 brands recording reductions of more than 50 per cent. The highest reported reduction is 96.45 per cent.
The scale is what makes this intervention different from routine price monitoring. Prices of more than 1,000 anti-cancer medicine formulations across different brands will come down from 9 November, according to reporting of the NPPA's figures. The authority has said the trade margin rationalisation for non-scheduled anti-cancer medicines was intended to improve the affordability and accessibility of essential medicines for cancer treatment.
What a trade margin is, and why it matters
A trade margin is the difference between the price a manufacturer charges a stockist or distributor and the highest price, the MRP, that a patient ultimately pays, excluding GST. It is the share of the final price retained along the distribution chain, by distributors, stockists, retailers and hospital pharmacies, between the factory gate and the patient.
The problem the NPPA is addressing is that this gap had grown very large for some cancer medicines. Critics and patient groups had long flagged the mark-ups accumulated across distributors, stockists, retailers and hospital pharmacies as a primary driver of unaffordable cancer treatment costs in India, according to reporting of the order. In some cases the price a patient paid was several times the price at which the medicine left the manufacturer.
The cap works by limiting that gap rather than by fixing one common price for every cancer drug. Under the new rule, the margin between the distributor price and the MRP cannot exceed 30 per cent of the MRP, excluding GST. That corresponds to a mark-up of about 42.86 per cent over the price paid by the stockist or distributor. Medicines that were already priced below the new limit cannot be made more expensive, and the order controls distribution margins rather than directly fixing the manufacturer's starting price.
The scale of the cuts, in the numbers as reported
The reported reductions are large but uneven, and the exact numbers depend on which snapshot of the NPPA's figures is used. An official factsheet released on Friday, 6 November 2026, put estimated patient savings at Rs 3,357.49 crore, calculated as the difference between original and revised prices applied to the volume of medicines sold between April 2025 and March 2026. By that snapshot, 70 companies had revised prices for 120 of the 137 medicines, covering 1,136 individual products, with reported reductions averaging 20 to 70 per cent and the largest at 96.45 per cent.
Reporting published on 8 November, citing the NPPA, gave a slightly different and later picture: 76 companies had reported revised MRPs for 1,225 formulations covering 121 drugs, with reductions in 1,031 formulations, and consumers were expected to save Rs 3,502.31 crore annually. The two savings figures are both attributed to the NPPA but come from different dates and different stages of companies' reporting, so they should be read as estimates at a point in time rather than as a single settled number. Both figures are projections based on past sales volumes, not savings already received by patients.
Individual examples reported from the NPPA's lists show how steep some cuts are. Zydus Lifesciences' Bryxta, a brand of bevacizumab injection used in the treatment of lung, colon, ovarian and cervical cancers, has been revised from Rs 25,995 to Rs 3,318. Reliance Life Sciences' BevaciRel has been reduced from Rs 24,079 to Rs 3,985, while Hetero Healthcare's CIZUMAB has been cut from Rs 15,658 to Rs 3,103. In prostate cancer treatment, Arvincare Pharma's ABIRONE, an abiraterone acetate tablet, has been reduced from Rs 41,250 to Rs 3,218.23, and Glenmark Pharmaceuticals' Abirapro from Rs 28,744 to Rs 5,768. Hetero Healthcare's PEG FILTERO, a pegfilgrastim injection used to prevent neutropenia in cancer patients, has been revised from Rs 9,093 to Rs 1,631, and Reliance Life Sciences' Peg-ReliGrast from Rs 5,331 to Rs 1,258.
Which medicines are covered, and which are not
The 137 medicines are described as non-scheduled, meaning they sit outside the routine ceiling prices applied to medicines listed in Schedule I of the Drugs (Prices Control) Order. Most non-scheduled medicines are ordinarily monitored only through a limit on annual MRP increases, so this order uses the NPPA's extraordinary public-interest power under Paragraph 19 of the Drugs (Prices Control) Order, 2013, to intervene directly in these medicines' prices.
The list spans chemotherapy, targeted treatments, hormonal medicines, immunotherapies and supportive medicines. Named products in the reporting include pembrolizumab, nivolumab, durvalumab, osimertinib, olaparib, denosumab, topotecan and bevacizumab, as well as azacitidine injections used for blood cancer, enzalutamide capsules for prostate cancer, fulvestrant injections for breast cancer, palbociclib capsules for breast cancer and pemetrexed injections used in lung cancer treatment. The order covers the listed medicines across strengths and dosage forms, including combinations, branded and generic products, imports and medicines protected by patents.
There are limits. The cap applies only to the 137 identified medicines and the specific formulations covered by the official notification, so other cancer medicines are not affected. The authority said 10 to 15 of the 137 identified anti-cancer drugs have not yet been launched in India, and the trade margin cap will also apply to these medicines when they enter the Indian market. Separately, the NPPA has fixed ceiling prices for 131 scheduled anti-cancer formulations under the same 2013 order, which is a different mechanism from this margin cap.
How the new prices were worked out
Manufacturers were required to recalculate their MRPs using their average distributor prices from March 2026, and the revised calculations use the prices charged to stockists or distributors in that month. Free medicines distributed under patient assistance programmes and direct government sales are excluded from the savings calculation. The notification, SO 5690(E), was issued on 17 October 2026 and will remain in force until further orders.
The decision followed recommendations of an expert committee constituted by the Directorate General of Health Services under the Ministry of Health and Family Welfare. The NPPA then notified the expanded trade-margin rationalisation measure on 17 October 2026 under Paragraph 19 of the Drugs (Prices Control) Order, 2013, which permits intervention in the public interest.
Companies must notify the NPPA of their revised prices, publish the reductions in newspapers, post them on their official websites, and communicate the changes to all retailers and hospital pharmacies. Manufacturers may undertake annual price increases in accordance with Paragraph 20(1) of the Drugs (Prices Control) Order, 2013, provided they continue to comply with the maximum permissible trade margin of 30 per cent. The NPPA website is updated on a rolling basis as companies submit their revised MRPs, which is why the counts of companies, medicines and formulations have kept changing in successive reports.
What patients should actually do, and what the cap does not fix
Patients can check revised medicine prices through the Pharma Sahi Daam mobile application and the NPPA website. The authority has directed retailers, dealers, hospitals and medical institutions to prominently display revised MRP lists on their premises and websites, and State Drug Controllers will monitor compliance by manufacturers, dealers, hospitals and medical institutions. Complaints about overcharging or violations of revised prices can be submitted to the authority by email at monitoring-nppa@gov.in, on its helpline 1800-11-1255, or by post to the Deputy Director (Monitoring), NPPA, YMCA Cultural Centre Building, 1 Jai Singh Marg, New Delhi.
The order also contains safeguards intended to protect availability as prices fall. It restricts manufacturers from reducing production without permission and requires notice before discontinuing a medicine. That matters because a price control that made a medicine unprofitable to supply could otherwise leave patients unable to find it at all, and the reporting on the order notes that price control only works if medicines stay available.
The cap addresses medicine prices, not the full cost of cancer care. Insurance coverage, diagnosis and treatment facilities remain relevant to whether patients can obtain the prescribed drugs, and hospital bills include much more than the medicines themselves. The immediate question, as one policy analysis put it, is whether the notified reductions actually reach hospital and retail bills from 9 November, including for patients buying patented medicines, and whether availability is maintained while the new prices bed in.
The 2019 pilot, and what comes next
This is not the first time the government has used trade margin rationalisation as a pricing tool. A pilot intervention in 2019 covered 42 non-scheduled anti-cancer drugs and reduced patient costs, establishing the proof of concept that the current, broader rollout builds upon. The expansion from 42 to 137 medicines reflects both that pilot's track record and sustained pressure from state governments, patient advocacy groups and civil society organisations about the gap between procurement prices and MRPs.
The remaining price submissions matter. As of 4 November, companies had reported revisions for 120 of the 137 medicines, and by the later reporting the figure had risen to 121 drugs covered by revised MRPs. The remaining medicines still need revised submissions from manufacturers, and the full savings potential of the scheme is expected to be realised only as those submissions come in and the NPPA publishes them.
There is also a wider legal context. The Supreme Court has been hearing a matter concerning price regulation, with the case scheduled for further hearing on 27 October 2026, when the court was expected to consider the government's position on extending price regulation beyond cancer medicines. For now, the 9 November change is confined to the 137 listed anti-cancer medicines, and whether the margin-cap approach is extended to other therapeutic areas will depend on both the courts and future government decisions.
Editorial disclosure
This article was researched with AI assistance and reviewed by the publisher before publication. Report factual errors through our contact page.
Frequently asked questions
Which cancer medicines are covered by the NPPA margin cap?
The cap covers 137 non-scheduled anti-cancer medicines across their strengths, forms and combinations, including branded and generic products, imports and patented medicines. It does not cover other cancer medicines outside the notified list, and 10 to 15 of the 137 drugs have not yet been launched in India.
When do the new cancer drug prices take effect?
The revised prices take effect from 9 November 2026. The NPPA issued the order, notification SO 5690(E), on 17 October 2026 under Paragraph 19 of the Drugs (Prices Control) Order, 2013.
How much will cancer drug prices actually fall?
Reported reductions average between 20% and 70%, with the largest single reported reduction at 96.45%. The fall varies by medicine: for example, Bryxta (bevacizumab) was revised from Rs 25,995 to Rs 3,318, while some medicines saw smaller cuts. Not every covered medicine falls by the same amount.
How much will patients save in total?
Estimates differ by reporting date. A factsheet released on 6 November 2026 put estimated savings at Rs 3,357.49 crore, based on April 2025 to March 2026 sales volumes. Later reporting on 8 November cited the NPPA as expecting annual savings of Rs 3,502.31 crore. Both are projections based on past sales, not savings already received.
How can patients check the new price of a medicine?
Patients can check revised prices on the NPPA website or the Pharma Sahi Daam mobile application. Retailers, hospitals and medical institutions have been directed to display revised MRP lists, and complaints about overcharging can be made to the NPPA by email at monitoring-nppa@gov.in or on helpline 1800-11-1255.